Language

English

Publication Date

3-17-2026

Journal

The Journal of Infectious Diseases

DOI

10.1093/infdis/jiaf572

PMID

41287255

PMCID

PMC13017828

PubMedCentral® Posted Date

11-25-2025

PubMedCentral® Full Text Version

Post-print

Abstract

Traditional vaccine clinical trials sample blood from all participants. In contrast, the test-negative immune correlates (TNIC) design only samples blood from participants who develop symptoms. We compared traditional to test-negative immune correlates methods in the mRNA-1273 severe acute respiratory syndrome coronavirus 2 vaccine efficacy clinical trial. Using a neutralizing antibody assay, hazard ratios were 0.48 (95% confidence interval [CI], .29-.73) and 0.55 (95% CI, .28-1.06) for traditional and test-negative methods, respectively. Analogous ratios for binding antibody assay were 0.69 (95% CI, .52-.94) and 0.78 (95% CI, .50-1.20). The results support use of the logistically simpler TNIC design.

Keywords

Humans, COVID-19, Antibodies, Neutralizing, SARS-CoV-2, Antibodies, Viral, COVID-19 Vaccines, Male, Research Design, Female, correlates of risk, correlates of protection, test-negative design, vaccines

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.